Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema

Table 1

Demographics and number of ranibizumab injections in both groups.

	Switch group	Ranibizumab group
Age (years)			0.37
Mean (±SD)	62.1 ± 7.5	63.4 ± 6.5
Median (min–max)	60 (50–76)	64 (53–72)
Gender			0.09
Male	9 (45%)	13 (56.5%)
Female	11 (55%)	10 (43.4%)
Number of ranibizumab injections before intermediary visit			0.64
Mean (±SD)	5.3 ± 1.2	5.5 ± 0.9
Median (min–max)	5 (3–5)	5 (3–5)

n: number; SD: standard deviation.